Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Hi everybody, and welcome to the quarter three report presentation of Surgical Science, which is also the first quarterly report presented by me. Tom Englund is the new CEO of the company. Next to me, here in the studio, I have Anna Ahlberg, our company CFO. We will use the time today to first present the report, and then we will take questions from the audience. To start off with, the Q3 report is a result that I and the Surgical Science team are quite pleased with. We show currency adjusted growth of 12% versus the previous Q3, with an EBIT margin of 20%, and we see a generally positive development across the entire business. As you know, we have two different business areas: Educational Products and Industry/OEM. And it's great to see that both of our business areas are now growing. Educational products grew 2% in comparison to quarter three last year and exhibited a 17% growth compared to the previous quarter, which indicates accelerating growth. The Industry/OEM segment grew by a strong 22% compared to the same quarter last year. Looking a little bit deeper into educational products during the second quarter, we said that the turnaround had come for educational products and that we saw increased customer activity and greater pipelines than before. It's good to see that this turnaround continued in quarter three, with a 2% increase compared to last year and 17% growth compared to the previous second quarter. All regions grew, but at slightly different paces. Europe was up 49%. North America increased by 4% and Europe by 6%. Versus the previous quarter. Last quarter we said that there's uncertainty about whether the business area will show growth for the full year, and that it partly depended on whether we receive the large tender. We can now say that the large tender will not affect quarter four regardless of the outcome. And this means that we don't expect it to show growth for the full year. We are very confident about the growth prospects of educational products for 2025 and beyond. Moving into Industry OEM, we show a solid 22% revenue growth, which is a continuation of the strong development we have had in the business area in the previous quarters. This business area consists of simulator sales, sales to medical device companies, as well as software simulation packages to robotic surgery companies. If we look at sales of simulators, they increased by 82% to 26 million. And so far this year, simulator sales have grown a whopping 182% to 84 million. We see a clear trend among customers to consider our simulators to be business-critical for a wider range of functions and disciplines within their company. This means that simulators are now actively being used in departments such as education, sales and marketing, as well as R&D. And this in turn means that the number of simulators per customer is increasing. And during the quarter, we also delivered the first units of our ultra-portable simulator to a very important industry customer of ours, DevRevs. Developmental revenues contracted by 20% to 9 million. This revenue is lumpy in nature, but we remain confident in the growth, and we have a very healthy pipeline of projects for the coming 12 months. Looking deeper at the license revenues, they increased by 17% to 65 million. We had a solid development during the quarter of our license revenues, and it's very positive for us to see that the robotics market is developing. With more entrants now getting closer to starting active sales or marketing of their products. Digital Motion and CMR Surgical announced that they had received FDA approval for certain procedures, and Johnson & Johnson, one of the world's largest medtech companies, had filed for and just received an IDE approval for their Ottawa systems, which is the step before the actual FDA approval. These new entrants, who are also our customers, will drive growth in the robotics market and, in turn, increase the training needs for robotics and therefore the demand for simulation. Regarding Dv5, we have no further news than what we already shared in the second quarter. Intuitive is targeting a full launch of the Dv5 system during mid 2025, and is currently conducting a controlled pre-launch to selected customers. These systems are equipped with clinical software only and do not have simulation on them, completely according to plan. And to finish off, Intuitive is an esteemed customer of ours, and we are working hard to ensure that Intuitive has a great digital experience, including simulation, in time for the full launch of the Dv5. Um. I have now been in the formal position for six weeks, and before that, I was in a six-week introduction period together with Gisli Henemark, the previous CEO. During these first weeks in the company, I've spent a lot of time with the team and our customers to understand the ins and outs of the market we operate in. I've had the opportunity to work alongside Gisli, who has been invaluable during the handover period, and on the slide to your right, the lower right picture shows an image from one of our introduction meetings in our office in Tel Aviv. And my focus, in addition to understanding the company and building relationships both internally and externally, has been to develop a plan and goals to help us achieve our short-term growth ambitions and longer-term market-leading ambitions that we have for Surgical Science. As we now look towards 2025, I'm filled with excitement and energy for the continued growth journey. We have world-leading products, a super strong, highly engaged, and global team. We have the stability and brand of a market leader, and we operate in a growing and rapidly developing market with prominent customers. We have challenges mainly related to our ability to handle rapid customer growth and operational scalability, but these are challenges that I feel confident we will be able to handle. And addressing these challenges will also help us build a much bigger and much more successful company. And with that, I would like to hand over the word to Anna to go over the financial numbers.
Thank you, Tom, and hi everyone. So starting with revenues per business area, as Tom said, we show growth for both our business areas, and our total sales were up 10% to just below 232 million. In local currencies, it was up 12%. And this is the first quarter in a very long time that we have experienced negative effects. As I'm sure most of you know, we are heavily dependent on the US dollar, where we have over 80% of our sales in that currency. And of course, for translation differences, we are also dependent on the shekel. As Tom said, in our Q2 report, we talked about the turnaround that we saw for educational products, and we continue to see and feel this momentum. We had some weak quarters before and a very weak Q1, but we now continue to see money flowing into the system, even though the picture is a bit different between different geographies. Sales were up 2% compared to Q3 last year, but 17% compared to the last quarter. For Q2 in Asia, we observed a significant increase over Q3 of the previous year, along with a smaller increase compared to Q2. China is an important market for us. And, you know, it's been affected by the anti-corruption campaign for quite some time, and we are still cautious to say that it's over. But sales there were on par compared to Q3 last year, a bit lower than Q2. And we also commented on India before because that market was affected by the election taking place, which impacted both Q1 and Q2. But now the administration is in place and we see very good development. Europe, as Tom mentioned, increased by 49% compared to Q2 and by 10% compared to Q3 last year. And if we look at the markets where we had the strongest development, as we talked about before, the money flowing into Eastern Europe, we see Poland and Bulgaria being very strong for the quarter. North America increased by 4% compared to Q2 but was lower than Q3 last year. The US market was on par, but we had a larger order in Brazil last year that affected the comparison numbers. Ind/OEM up 22% and license revenues ended at 65 million, up 17%. We also see a continued very strong development for our simulator sales within the Industry/OEM segment, with an increase of 82%, ending at 26 million. Development revenues were down slightly. I will come back to that on the next slide where we see our different revenue streams, and you have them also divided by business area in the report. License revenues are up, as we discussed. And also then as a percentage of total revenues. 28%, compared to 26%. Q3 last year, emphasizing again that, as always, this is lumpy for new entrants since they purchase their licenses in batches. And we have seen that for 2024, sales of new packages have been weaker than last year too. To new entrants. Our simulator sales, if we combine simulator sales within Educational Products and Industry OEM, were the strongest we've had since Q4 2022. And it was plus 10% compared to Q3 last year and plus 18% compared to Q2. Development revenues, as I mentioned, were a bit weaker if we compare to Q3 last year. But as you can see, that was also a very, very strong quarter. If you compare it to the other quarters in 2023, it was still a bit stronger than in Q1 and Q2. This is industry development. Revenues are all within the Industry/OEM segment, and they consist of both robotics projects as well as projects tied to sales of simulators. Moving on to look at our costs and the EBIT margin for the quarter. Our gross margin was 69%, the same as in Q3 last year, and a bit stronger than in Q2 when it was 68%, despite the fact that we had a higher share of license revenues in Q2. And this is then due to the volume factor that we had, with a higher volume of simulators now, meaning that fixed costs are distributed over a greater number of simulators. Comparing to Q3 last year, the increased share of license revenues had a positive effect on the gross margin. We also had a favorable product mix. However, our average sales price was slightly lower. Sales costs were a bit higher than last year, but on par with Q2. In Q3, we had lower activity regarding congresses and trade fairs than in Q1 and Q2, and that is the pattern we have every year. So, that is normal; the lower costs due to this were offset by the fact that during the quarter we had higher agent fees, and that is really dependent on where we sell during the quarter. 18% of sales, the same as Q3 last year. Administration costs were on par with last year and a bit lower than Q2, representing 8% of sales, and then there are the R&D costs. They were slightly higher than in Q2 and significantly, approximately 10 million, higher than in Q3 last year. We continue to invest in our R&D organization. We continue to employ skilled software developers. We also activated less, which depends on the type of projects we are working on. And we also, as I mentioned before, had less development revenues, and that means that we move fewer costs to the cost of goods sold. So, it becomes a bit technical here, but you can find our R&D costs in three different lines. The cost of goods sold, the actual R&D line, and then in the balance sheet where we activate, if we combine these and look at the total R&D costs, we see that they did not increase by 10 million. They increased by 5 million, from 58 to 63 million. The item 'other' consists primarily of options or option programs and their effects. And in Q3, we experienced a more significant impact related to the option program. And that is attributable to the new program that was approved by the AGM in May. And that is the Swedish part of the program where the participants receive the premium as a bonus, and we pay social costs on them. And it's also the IFRS 2 effect. And that was the same now in Q3 this year as in Q3 last year. But it's a higher effect in Q3 than in previous quarters. Organization. Going out of Q3 this year, we had 270 employees in the company, compared to 260 going out of Q3 last year. And you can see the split between the different sites down to the right. The adjusted EBIT margin for the quarter was 22% compared to 27% in Q3 last year and up from Q2 when it was 19%, and for the nine-month period, we had an adjusted EBIT margin where we then adjust for costs attributable to our acquisitions, amortization, and depreciation. The margin was 20% for the nine-month period compared to 26% for last year. Our finance net was a positive 7 million. Most of that is attributable to interest on our bank balances. And then we also have items related to the revaluation of internal loans to our subsidiaries and IFRS 16 effects. The net result for the quarter was 43 million. Our cash flow for the quarter was a bit weaker than what we have been used to from operating activities. It was a plus of 22 million SEK in that amount. We have a minus of 9.4 due to the fact that we paid out taxes in Israel on a previous financial year, and then we had a negative change in working capital amounting to 32 million. Inventory changed marginally. However, our accounts receivables increased significantly. I usually talk about the accounts receivables and the work that we always do on that. We've been working very diligently on it for quite some time, and we had a very big positive effect after getting the A/R stock from 3D Systems when we acquired Simbionix. And then we continued to work on that. And we've had a very nice development, especially in the US, which is our largest direct market, where there's always something to work on. And so, of course, I've said before that I don't think this will decrease much more if we look at the average accounts receivables as a percentage of rolling 12-month sales. But of course, we would not like it to go up. We don't see any general increasing trend or any cause for concern. It's more a timing issue that when orders and payments come in, we had quite significant amounts falling due in the beginning of October and then cash flow from investing activities. That's mainly investments in development costs. The item from financial activities was very small for the quarter, and then we had a negative exchange rate difference in cash amounting to 7 million. That meant we ended the quarter with 666 million SEK in our bank balances. And with that, we conclude this part of the presentation. And I think we can open up for questions.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ulrich Trattner from Carnegie. Please go ahead.
Thank you very much, and thanks for taking my questions. A few of them on my end, and I'll start off with. You mentioned in the report healthy order intake for the educational segment. And since you don't disclose orders, can you talk a little bit more about what this actually entails? And in addition, based on the current tender activity out there, are you able to provide us with some kind of direction on the average selling price in your data since what we have seen over the last few years, or at least the last few quarters, is an average selling price for edu modules coming down. So. So what? Just based on the tenders and the specifications of these, in what direction is this moving? That would be my first question, please.
Hi.
And thank you for the question. I can start with the first part of the question, which relates to the traction that we see, generally speaking, in the market. And um, what we saw a year ago was that the market started contracting, and due to both budget issues and also general inflation, it got harder for our customers to procure simulation products. Broadly speaking, globally. And this has resulted in the negative trend that we've seen for educational products until the turnaround came last quarter. The pipelines and opportunities we had during this period did not simply disappear. They were, the payoffs were still out there. It was just that they didn't convert into sales. And what we see now, with the money flowing back into the systems globally but in different capacities, is that these tenders are being reactivated and turned into orders. And we saw some of that in quarter two. And we saw an even stronger development in quarter three. I would say that the main reason for the slow activity and declining sales in educational products is not that we estimate we lose market share to competitors or that deals completely vanish, but rather they have been put in the freezer and now they're coming back. So this means, then, that everything we have worked on up until now in terms of sales activity, we think a lot of that can translate into sales.
And then continue. I can continue a bit on your question about the average selling price. When we sell our simulators, it includes the hardware. And then we have a basic software package that is sort of included in that. And then on top, we sell. We have a library, often containing different modules with more advanced procedures that you can purchase. And of course, the more software we sell on each hardware platform, the better it is also for the margin. What we saw last year, when the market started to contract, is that the hospitals were hit by inflation, and the budgets were set before that. So they didn't have enough money. They still had the demand and wanted to purchase. But what happened in the beginning was that they then purchased the hardware platforms with less software. And that meant, of course, that our gross margin was affected by that. So it's important for us to sell. Of course, we can also upsell. And we do that. We have sales that are pure software on the existing hardware platforms. Um, and I would say that the product mix here is more important for our gross margin because we have a broad range of products. Some of them are not that large. We have them because it's important for us to have a full range so that we can supply for a full, large tender. We see that we have a very high win rate for the large tenders. Therefore, that is important for us. But of course, with lower volumes, some of these products might not be sold separately as much. And with lower volumes, the margin on them is generally less. I hope that answered your question. Yeah. Yeah.
Kind of, thanks, Tom. And potentially, could you give us some kind of insight here because that was my point, where I was getting at that we saw an average selling price come down last year due to budget restrictions that are out there, and if you're in the current tender, are you seeing a shift in activity to be more willing to buy more advanced simulators or with a more advanced software package.
Yeah. No. Versus. Yeah.
No, definitely. I should say that. Absolutely. Then sometimes, of course, since, you know, the large tenders are available, there is a long lead time. So often, the prices and everything are set. There is a lag in the system due to that. The lead times. But yes. Generally speaking, yes that's correct.
Okay.
Um, but I would say that the product mix here is more important for our gross margin because we have a broad range of products. And if I were to turn to OEM, um, and consider what we have seen here in the last few quarters, and I ask the same question in Q2, I note very strong sales in OEM simulator hardware, and I would guess that indicates very strong demand and continued demand outside of robotics. Um, and again, the same question as in Q2 is, have you reached some type of inflection point when addressing these sort of OEM non-robotic customers, and has their behavior changed or anything?
I think that the medical device part of the industry, OEM business, is an absolutely fantastic opportunity for us to continue to see growth and some things that we perhaps don't speak enough about here in these calls. We tend to focus a lot on the surgical robotics side of the business, and you can definitely say that we have seen a very strong increase from relatively low numbers. It should be noted 182% is great, but it comes from a low base. But what I said in the beginning holds true, meaning that we see that simulators are used within med device companies in a much broader and wider number of functions. Previously, they might have been used primarily for educating surgeons about the new equipment. But now we also see that the simulators are being used in R&D activities and also as sales and marketing tools for the med device companies, sales force and marketing functions. So they're used much more broadly. And in that, they're also becoming a more critical tool for these med device companies. And if you go into any typical large med device company such as Medtronic or Boston Scientific, they conduct a lot of product launches every year with different types of medical devices that require training for both sales and marketing personnel, as well as, of course, for surgeons who are going to use the tools. And there we see a very strong potential to continue to grow the simulator sales across a wide range of companies and across a wide range of different application fields. Does that answer your question?
Yeah. Yes, absolutely. And potentially just a follow-up on that. It's kind of back to the original question. Is it your focus on these customers, or is there a change in customer adoption of simulation for these products, or is it kind of both?
I think it's a combination. It's a combination of both. This has been a clear and strategic approach for us to engage more deeply with these customers. And by doing so, we also communicate the value much more strongly to them. And then in turn, that drives the user uptake on their part. So the total addressable market here is very big. And that's something that we are starting to realize in real sales.
Okay, great. And, as well, a question on the OEM. And you mentioned this ultra-portable lightweight simulator. Um, what is this?
Yeah.
So if you take, for example, the sales and marketing teams at our customers who are going to use simulation as a tool to either sell and market the med device companies' products. Right? They usually do so at the customer location, which could be in a hospital, or it could be at a conference or a trade show. Right. And then, the need to have an ultra-portable device that is still extremely realistic in the experience when you run the simulator is very significant for our customers. Having everything ultra-portable in a suitcase that you can demo and show to potential customers means a lot to them. And we see this trend also in the surgical robotics field, where the robotics manufacturers want to showcase simulation and the robotics experience outside of the console itself. Right. So historically, we have primarily sold software licenses to the surgical robotics companies that are then used on the console. But we see an increased demand and interest for surgical robotics companies to sell simulators with the simulation on top that are more ultra-portable and outside of the console.
Okay. That's great. Thank you, Tom. And the last question on my end would be to you, Anna. And you ended the presentation talking a little bit about this. But I'm in Q3 here. I'm focusing on operational cash conversion as well as free cash flow. And you talk about the accounts receivable remaining stable in percentage of sales. But what should we extrapolate from Q3 and what should be done next? And obviously, there are the effects of tax based on historical data. Tax rates in Israel. But what level here is considered a sort of sound foundation? Because we were coming from quarters where you've had fairly high cash conversion Now down to fairly poor.
Yeah. And we should, I mean, we should have. Good cash conversion, then I think that we've had very, very good. And as I said. We've also had a significant effect from the fact that we could work extensively with the A/R. Stock that we received when we acquired Simbionix, and then we. But then we continued to work on that. And what I can say is we have a healthy. Uh, that's something we A/R stock is something we follow closely and of. Of course, sometimes this depends on who you sell to, especially if it's the larger industry. For companies, for example, it might be that you have longer payment terms. , but it is just a single day that you measure this on. It's on the 30th of September. Right? So, timing is sometimes a bit difficult and might affect the number on that specific day. I am not, I'm not worried about our accounts receivables stock. And it's something you constantly have to work with, for sure. But we don't. As I said, we don't see any cause for concern or any general sort of shift in trend or, you know, what have you.
Of course, sometimes it depends on who you sell to, especially if it's a larger industry.
That's that's great.
It can also, of course, differ between different countries, I must say, you know, so yeah.
And since you mentioned different countries, perhaps I can end with one last question. Which countries are sort of best in terms of payment cycles and which ones are underserved?
You know, in some countries, it might be that it takes a longer time for payments, you know, we have distributors in most countries outside of the US, and it sometimes takes longer for them to pay, even though we have general payment terms towards them, etc. And so, I will not pick or choose specific countries. But the important thing for us is that we feel we have a healthy stock. And we also mentioned before that we have a very strong cash position. So if we need to use it somehow, we might do that also for a shorter period of time, you know, to give people maybe a longer payment term, or for large med device companies, or what have you.
Okay, great.
Um, that was all the questions on my end. I look back into the queue. Thank you, Tom.
Thank you, Alex. Course, sometimes depending on who you sell to if it's the larger industry.
The next question comes from Victor Högberg from Danske Bank. Please go ahead.
Yeah. Good morning. Regarding the educational segment for the full year, it's no surprise that you may not see growth for 2024 over 2023. But is it the only swing factor, the large tender you previously mentioned? Or are there other factors in play as well? Uh, just trying to triangulate the size of it. The largest order that we do know about is the €7 million order received two years ago. I would assume this is lower than that. So is there anything you could help with regarding the magnitude of this and the swing factors in terms of growth this year?
I can.
Say that. Hi, Victor, by the way. Sorry. I can say that, um, the swing factor is definitely a large order, but it's definitely not only that. In general, we see a strong recovery in the business across the board, in all countries. We operate in many countries with many different budgetary systems and different economic situations. And we have quite a large pipeline. Right. And it's difficult for us to predict exactly how these tenders will come back and how fast the recovery will be, country by country, and then try to extrapolate that into some sort of global development because it's also a moving target. Right. So I would say that that's the main factor. And Guiseley said to use the quote. It's a race against the clock. We see recovery. It's coming. We saw recovery from quarter two to quarter three. And we have, you know, good hopes for continued growth in the educational products segment. So that's what I would like to describe it.
Good morning. Um, and on the R&D side, in your CEO letter, you're talking about some challenges in getting the organization in place to be able to deliver, and it seems like a nice problem to have, but what do you need to do in order to get it? All right, and according to plan, is it a worry for you or just business as usual to get all of this in place?
It's a very good question. And you might be alarmed. Is there a challenge? There are always challenges at companies, right? Especially companies that are growing at the pace that we are. And I also feel, to start off with, very confident that the global team—the fantastically passionate, engaged, and very competent and experienced team that we have—will be able to address these challenges, specifically those related to R&D.
They.
Pertain to our ability to scale our capacity in R&D, to handle both customer requests and customer projects that come in, broadly speaking, in both business areas and throughout the business. And there are a lot of things that we need to do in order to increase this capacity. And some of them are, of course, hiring more people and onboarding them in an efficient and successful manner. But it's also the ways of working, the tools we use, the platforms we write code on, and so on where we can improve. And of course, that will also then contribute to increasing capacity. So it's definitely a very high focus area for us right now, and it will be for the coming year and years.
It's a very good question. And a follow-up on that one. Given your experience in other companies, um, is this something which you think you want to change about the way the company has been working, tweaking it, or is this in line with previous modes of operation? Just thinking about the flavor you're adding now that you're CEO, what you're looking for.
I think that, uh, first of all, I inherit here, uh, the CEO position of a company that has been tremendously successful with the previous team and leadership under Gisli, which is a fantastic position to be in. And we look at how we're going to address this specific question, which I understand you are asking about, and I think that we have really good, solid developers in all the different offices that we have in Surgical Science, and they are working in a very efficient and professional manner. I do think that we have some challenges, which come with the integration of the different platforms that we have from the various companies we have acquired. If you're familiar with Simbionix, graphics, and mimics, they all come with different technical platforms into Surgical Science. So there we have a specific challenge in how to consolidate the entire code base into a uniform system and align our ways of working around that. So that's a specific challenge that we have due to the M&A, M&A that we have done.
Okay.
Um, is that major work to be done? Um, would you assume that it has been, uh, bridged or done already, given that it was acquired two years ago? Yeah. So I would assume it's just final tweaks on it or.
Yeah, this is work that was started way back and it's continuing. I think that the necessity for improvement in this area has largely to do with the fact that we see so much uptick in customer activity and many more higher inbound requests coming in to us. So it becomes, you know, a more acute matter, but I think we're making great progress. And I'm very confident in the team's ability to handle this challenge. They're awesome.
Okay, great. Final question for me, and there might be an external question, not up to you, but with the tariffs that might be put into place for exports into the US, have you considered any scenarios on this, given that the US is a large market and you're selling and shipping a lot of products into it? Um, any thoughts on that one or is it too early?
Maybe it's early, of course. Uh, one initial thought is that initially, it looks like it might affect products, not services or licenses. Uh, as you know, our products are primarily shipped from Israel. Uh, where it might not be the case. So we don't see any cause for alarm or concern regarding this for us at this early stage. And then, as you know, we have a smaller production unit in the US. And we also have teams working on our software projects in the US.
And are those sites able to scale up if needed? Uh, would you be willing to or is it possible to expand those production sites in the US? Um, to source locally basically, if that would be a requirement.
We commented earlier that we had an increased R&D spend for the quarter compared to the previous quarter. Right. And this is a long-term investment for us. To cope with the increased demand, we invest that money into all the different sites. So, we grow all the sites with headcount and we see that we will do so also for the foreseeable future. So we are investing, and we don't make any specific plans due to tariffs, because, you know, we don't want to change those investments around. We actually think that it's quite beneficial to have a distributed developer network across our offices.
So it becomes, you know, a more acute matter, but I think we're making great progress. So it becomes, you know, a more acute matter than, but I think we're making great progress. Thank you very much.
Thanks, Victor.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. The next question comes from Christian Binder from Redeye. Please go ahead.
And start taking my questions. Um, a couple of follow-ups you've already discussed a little bit in terms of being able to handle higher volumes. Um, and that's going to be achieved through both, um, new hiring but also increased efficiency. Could you specify a little bit more? Um, do you expect to make new hires selectively in certain areas, or can we, um, expect a quite marked increase in employees and corresponding cuts, so to speak?
Uh, hi, and thank you for the question. So, first of all, regarding the investments we make in people, we will implement them quite broadly across the different offices, as I just mentioned. In R&D. And then, when it comes to our ability to handle increased capacity, it is very important to have a focus on what I call operational scalability, which means that you increase the output with the same resources in place. And this is how we are also going to achieve our profitability targets long term. To achieve our profitability targets long term. And the way you do that is by becoming more efficient. And this does not, of course, only apply to R&D, but it applies to all the different functions that we have. And the way you get more efficient in R&D is through the use of a similar code base, ensuring that you work on one unified code, which allows you to branch out rather than maintain different code bases for the various customers that we have. That means that we can turn a customer request into the delivery of a final software product in a shorter time period, and also that all customers can benefit from the different innovations we implement in the code and the functions we deliver, since they are part of the common branch, so to say. And then there are also other aspects like languages, work methodologies, processes, and automation tools that we can develop. So it's like a very big array of different activities that all will drive capacity increases and our ability to serve our increasing customer base.
Perfect. It's very helpful. And, um, you already mentioned that, uh, obviously the educational product is unlikely to grow this year. Uh, but just in general, can we expect a more normal pattern this year in terms of Q4 being clearly the best quarter sales-wise? Or is it too early to tell?
Uh, yeah. Hi, Christian. You know, we never give out short-term forecasts. We have our long-term financial goals. And then this year, we talked more, maybe, about the short term because we had the Q1 that we had, etc. . And yes, Q4 is usually the strongest, but last year it was not. And that was actually the first time many of us experienced that. So, uh, I mean, Q4 should be a strong quarter, but we cannot give any specific comments on this one. Usually, the orders, I mean, as we said last year, it's important to remember that the orders typically come pretty late. In Q4 last year, we still had all these discussions. There was no reduction in demand and no change in competition or anything like that. So that is important to remember that it was due to the fact that the hospital simply did not have the funds left in their budgets when they came to Q4.
And then to round off, um, I mean, it's obviously been discussed before. Um, but when it comes to capital allocation, um, are you going to be, uh, pretty internally focused in terms of, you know, investing in the organization, developing the organization in the coming year, or are you planning to use the cash pile of around 660, 670 million Swedish for, for example, additional M&A?
We have said repeatedly that we will have a very strong organic growth agenda and ambition. And we also continuously look at inorganic opportunities. We have done consolidation of the market already, and we will continue to explore those options. So you should consider us capable of allocating those funds towards growing the business both organically and inorganically.
Perfect. That was awesome. Perfect.
Thanks, Krista.
Okay, so let's see if we have some, uh, written questions here. Um, there is a question if we will release information when we win the big European tender; we have not said where the tender is. So we said it's a big tender that we talked about in Q2. Usually, we don't have large orders. We have orders of different sizes. We usually don't go out with separate press releases unless it's like the US order that we had in 2022, which was a major press release because it was so big. But yes, we will, of course, follow up and provide information on this one since we mentioned it. So yes. And then we also have someone asking about if we could use our cash to buy Bitcoin. No, we don't think so. We believe there are better uses for our funds, as we just discussed in the plans we have. And then on the Dv5, there are some questions. If it's launched mid 2025, when do they usually buy licenses? Um, the way it is today is that the customer usually, it's sold as SIM. Now, it is a separate simulation package. And you can either purchase it with the robot, which is the case in most situations. And then there's also a subscription to that. And for us, we get paid. Then afterwards, getting a report on how much has been used. Uh, and again, as we said, we cannot really comment on more than we have done on the DB5. Uh, it's also a question if we should expect a large one-time jump in license revenues. Um, we have been asked that before. And as for coming back to that? Tom mentioned that we are working with Intuitive towards the timeline. There is no simulation on the DB5 right now. Uh, and a lot of things will be added going forward. And when they do the actual commercial launch, um. Then we also have a question on AI and AI tools for our software development.
Yeah, it's definitely on the, on the plan.
Then afterwards getting a report on how much has been used.
Plan of not just the R&D teams, but broadly in the company to employ AI more. More in the business, both primarily as a productivity-enhancing tool.
And then there's also a question about the buyback of shares. And that is correct. On the First North Growth Market, we're not allowed to do this type of transaction. We cannot purchase our own shares for that. You have to be on the main market. I think that also concludes the written questions. Thank you for all the questions.
Then afterwards, getting a report on how much has been used.
Any more questions before we round off?
Then afterwards, getting a report on how much has been used.
That's all from us. Thank you and have a great day. Bye bye.
Then afterwards getting a report on how much has been used. Bye bye.



















